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2) Cell transplantation focusing on induced pluripotent stem cells: There is an increasing interest in the iPS cells and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safetyrelated concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPS cells. In this lecture, the pre-clinical investigations of cell therapy for SCI using neural stem/progenitor cells derived from iPS cells, and their safety issues in vivo are outlined.
3) Diffusion tensor tractography: Recent advances in MRI technology have led to the development of diffusion tensor tractography (DTT) as a potential modality to perform in vivo tracing of axonal fibers. We demonstrated the effectiveness of DTT to visualize both intact and surgically disrupted spinal long tracts in common marmosets using hemisection and contusion injury model. DTT clearly illustrated spinal projections such as the corticospinal tract and afferent fibers in control animals and depicted the severed long tracts in the injured animals. Histology of the spinal cords was consistent with DTT findings, verifying the accuracy of DTT.
Laboratory animals are important bioresources that greatly contribute to advancements of medicine and biology. Especially, the laboratory mouse (Mus musculus) is the mammalian species that is most widely used because of the availability of the abundant genetic information and the technologies for gene modifications. Since the establishment of RIKEN BioResource Center in 2001, the Bioresource Engineering Division, my laboratory, is the sole technology division at BRC. Since then the division has been in charge of the development of bioresource-related techniques, especially reproductive engineering techniques applied to mice and stem cell technologies, and of maintaining and distributing these bioresources at a high quality. The specific functions of the division are: (1) cryopreservation of embryos and gametes; (2) microinsemination (sperm injection); (3) nuclear transfer; and (4) the establishment of new stem cell lines and generation of new animal models. Our laboratory may be the only one in the world that uses all four technologies at the highest level, thanks to the big efforts of laboratory members. Additionally, I would like to stress that the high achievements of my laboratory depended largely on highly recognized collaborators outside RIKEN. Our team's strong point is that we can combine our techniques with genetic and biochemical analyses, so that we may solve important biological questions in a unique and refined way.
